Drugmaker GSK buys US vaccine firm for up to $3.3 bn

British drugmaker GlaxoSmithKline on Tuesday snapped up US biopharmaceutical firm Affinivax for up to $3.3 billion, expanding further into vaccines before the demerger of its consumer health care arm.

This article was originally published on this website.

Lawyers Lookup